Different degree of cytokinemia and T-cell activation according to serum IL-6 levels in critical COVID-19.

ABSTRACT:

Introduction

Tocilizumab, a humanized anti-interleukin-6 receptor (IL-6R) antibody, is recommended for the treatment of severe to critical coronavirus diseases 2019 (COVID-19). However, there were conflicting results on the efficacy of tocilizumab. Therefore, we hypothesized that the differences in tocilizumab efficacy may stem from the different immune responses of critical COVID-19 patients. In this study, we described two groups of immunologically distinct COVID-19 patients, based on their IL-6 response.

Methods

We prospectively enrolled critical COVID-19 patients, requiring oxygen support with a high flow nasal cannula or a mechanical ventilator, and analyzed their serial samples. An enzyme-linked immunosorbent assay and flow cytometry were used to evaluate the cytokine

SUBMITTER: Lee CM 

PROVIDER: S-EPMC10110916 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature